Psoriatic ArthritisUVIPWPNCT07386717
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
An observational study of Psoriatic Arthritis and Upadacitinib, run by Peking University First Hospital at 1 site in China.
Trial summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- How many people
- 70 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2024to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Diagnosis of psoriatic arthritis according to established classification criteria
Who may be able to join
- Age ≥ 18 years
- Diagnosis of psoriatic arthritis according to established classification criteria
- Treatment with upadacitinib or an interleukin-17 inhibitor at baseline
- Availability of baseline and follow-up clinical data over 24 weeks
Who cannot join
- Diagnosis of other inflammatory arthritides
- History of malignancy or severe uncontrolled infection
- Incomplete clinical data preventing outcome assessment
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis: A Cohort Study
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life. Although targeted therapies such as Janus kinase inhibitors and interleukin-17 inhibitors have demonstrated efficacy in randomized controlled trials, real-world comparative evidence between these treatment strategies remains limited.
This observational cohort study aims to compare the real-world effectiveness and safety of upadacitinib and interleukin-17 inhibitors in patients with PsA over a 24-week follow-up period. By evaluating clinical outcomes under routine clinical practice conditions, this study seeks to provide evidence to support individualized treatment selection in PsA management.
Read the detailed description
This is a real-world, observational cohort study conducted at Peking University First Hospital. Adult patients diagnosed with psoriatic arthritis will be enrolled and followed for 24 weeks in routine clinical practice.
Participants will be categorized into two cohorts based on treatment exposure at baseline: patients receiving upadacitinib and patients receiving interleukin-17 inhibitors. Treatment decisions are made by treating physicians according to standard clinical practice and are not influenced by the study protocol.
Clinical assessments will be performed at baseline and during routine follow-up visits within the 24-week observation period. Effectiveness outcomes will be evaluated across musculoskeletal and dermatologic domains, and safety outcomes will be monitored throughout follow-up. This study does not involve experimental interventions.
- Conditions
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- Keywords
- Interleukin-17 Inhibitors, Upadacitinib, Psoriatic Arthritis
- Medical subject headings
- Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1: Upadacitinib-Treated PsA Patients | Adult patients with psoriatic arthritis receiving upadacitinib as part of routine clinical care and followed for 24 weeks. | |
| Cohort 2: IL-17 Inhibitor-Treated PsA Patients | Adult patients with psoriatic arthritis receiving interleukin-17 inhibitors (e.g., secukinumab or ixekizumab) as part of routine clinical care and followed for 24 weeks. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical effectiveness of treatment
Changes in joint and skin disease activity assessed using validated clinical measures during the 24-week follow-up period.
Measured: Baseline to Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start1 Jan 2024
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psoriatic ArthritisStudies of the same condition, open and under way.
- More trials run by Peking University First HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking University First Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07386717
- Sponsor's protocol ID
- UVIPWP_V1
- Acronym
- UVIPWP
- Status last verified
- Jan 2026
- First submitted
- 27 Jan 2026
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis: A Cohort Study
- ClinicalTrials.gov ID
- NCT07386717
- Acronym / sponsor ID
- UVIPWP / UVIPWP_V1
- Conditions
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- Keywords
- Interleukin-17 Inhibitors, Upadacitinib, Psoriatic Arthritis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- Peking University First HospitalUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life. Although targeted therapies such as Janus kinase inhibitors and interleukin-17 inhibitors have demonstrated efficacy in randomized controlled trials, real-world comparative evidence between these treatment strategies remains limited.
This observational cohort study aims to compare the real-world effectiveness and safety of upadacitinib and interleukin-17 inhibitors in patients with PsA over a 24-week follow-up period. By evaluating clinical outcomes under routine clinical practice conditions, this study seeks to provide evidence to support individualized treatment selection in PsA management.
Detailed description
This is a real-world, observational cohort study conducted at Peking University First Hospital. Adult patients diagnosed with psoriatic arthritis will be enrolled and followed for 24 weeks in routine clinical practice.
Participants will be categorized into two cohorts based on treatment exposure at baseline: patients receiving upadacitinib and patients receiving interleukin-17 inhibitors. Treatment decisions are made by treating physicians according to standard clinical practice and are not influenced by the study protocol.
Clinical assessments will be performed at baseline and during routine follow-up visits within the 24-week observation period. Effectiveness outcomes will be evaluated across musculoskeletal and dermatologic domains, and safety outcomes will be monitored throughout follow-up. This study does not involve experimental interventions.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cohort 1: Upadacitinib-Treated PsA Patients | – | –Adult patients with psoriatic arthritis receiving upadacitinib as part of routine clinical care and followed for 24 weeks. |
| Cohort 2: IL-17 Inhibitor-Treated PsA Patients | – | –Adult patients with psoriatic arthritis receiving interleukin-17 inhibitors (e.g., secukinumab or ixekizumab) as part of routine clinical care and followed for 24 weeks. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Diagnosis of psoriatic arthritis according to established classification criteria
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- Diagnosis of psoriatic arthritis according to established classification criteria
- Treatment with upadacitinib or an interleukin-17 inhibitor at baseline
- Availability of baseline and follow-up clinical data over 24 weeks
Key exclusion criteria (3 listed)
- Diagnosis of other inflammatory arthritides
- History of malignancy or severe uncontrolled infection
- Incomplete clinical data preventing outcome assessment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Clinical effectiveness of treatment
Time frame: Baseline to Week 24
Changes in joint and skin disease activity assessed using validated clinical measures during the 24-week follow-up period.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Psoriatic Arthritis
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
RecruitingPhase 4
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic Arthritis (PsA)
Active, not recruitingPhase 3
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Psoriatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriatic Arthritis and Upadacitinib, run by Peking University First Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical effectiveness of treatment (time frame: Baseline to Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.